JP2024526155A5 - - Google Patents
Info
- Publication number
- JP2024526155A5 JP2024526155A5 JP2023578891A JP2023578891A JP2024526155A5 JP 2024526155 A5 JP2024526155 A5 JP 2024526155A5 JP 2023578891 A JP2023578891 A JP 2023578891A JP 2023578891 A JP2023578891 A JP 2023578891A JP 2024526155 A5 JP2024526155 A5 JP 2024526155A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- use according
- egfr
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214769P | 2021-06-24 | 2021-06-24 | |
| US63/214,769 | 2021-06-24 | ||
| US202163277550P | 2021-11-09 | 2021-11-09 | |
| US63/277,550 | 2021-11-09 | ||
| US202163280521P | 2021-11-17 | 2021-11-17 | |
| US63/280,521 | 2021-11-17 | ||
| US202263321615P | 2022-03-18 | 2022-03-18 | |
| US63/321,615 | 2022-03-18 | ||
| PCT/US2022/034754 WO2022271964A1 (en) | 2021-06-24 | 2022-06-23 | Erk1/2 and shp2 inhibitors combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526155A JP2024526155A (ja) | 2024-07-17 |
| JP2024526155A5 true JP2024526155A5 (enExample) | 2025-06-24 |
Family
ID=84545944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578891A Withdrawn JP2024526155A (ja) | 2021-06-24 | 2022-06-23 | Ｅｒｋ１／２およびｓｈｐ２阻害剤の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299388A1 (enExample) |
| EP (1) | EP4358965A4 (enExample) |
| JP (1) | JP2024526155A (enExample) |
| KR (1) | KR20240096444A (enExample) |
| AU (1) | AU2022300368A1 (enExample) |
| CA (1) | CA3222772A1 (enExample) |
| IL (1) | IL309401A (enExample) |
| MX (1) | MX2023015298A (enExample) |
| TW (1) | TW202317124A (enExample) |
| WO (1) | WO2022271964A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107922387B (zh) * | 2015-06-15 | 2024-11-22 | 阿沙纳生物科学公司 | Erk1与erk2的杂环抑制剂及其在癌症治疗中的应用 |
| TWI852912B (zh) * | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| JP7337174B2 (ja) * | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| US20230027072A1 (en) * | 2019-10-28 | 2023-01-26 | Asana Biosciences, Llc | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
-
2022
- 2022-06-23 US US18/572,404 patent/US20240299388A1/en active Pending
- 2022-06-23 IL IL309401A patent/IL309401A/en unknown
- 2022-06-23 WO PCT/US2022/034754 patent/WO2022271964A1/en not_active Ceased
- 2022-06-23 CA CA3222772A patent/CA3222772A1/en active Pending
- 2022-06-23 MX MX2023015298A patent/MX2023015298A/es unknown
- 2022-06-23 EP EP22829313.0A patent/EP4358965A4/en not_active Withdrawn
- 2022-06-23 JP JP2023578891A patent/JP2024526155A/ja not_active Withdrawn
- 2022-06-23 AU AU2022300368A patent/AU2022300368A1/en not_active Abandoned
- 2022-06-23 KR KR1020247002544A patent/KR20240096444A/ko active Pending
- 2022-06-23 TW TW111123544A patent/TW202317124A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van der Kleij et al. | Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology: MBA van der Kleij et al. | |
| US20240299388A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| Dziadziuszko et al. | Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP) | |
| Lovly et al. | Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies | |
| AU2017329090B9 (en) | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor | |
| JPWO2023140329A5 (enExample) | ||
| US20240285625A1 (en) | Erk1/2 and kras g12c inhibitors combination therapy | |
| Martinelli et al. | Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK | |
| Giommoni et al. | Results of the observational prospective RealFLOT study | |
| JP2024505680A5 (enExample) | ||
| JP7504097B2 (ja) | Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法 | |
| JP2023553532A5 (enExample) | ||
| TW202140029A (zh) | 用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合 | |
| TW202304438A (zh) | 使用貝伐拉非尼及考比替尼或使用貝伐拉非尼、考比替尼及阿替利珠單抗的組合療法 | |
| Higuchi et al. | High clinical concordance of drug resistance in patient-derived orthotopic xenograft (PDOX) mouse models: first step to validated precise individualized cancer chemotherapy | |
| Piha-Paul et al. | A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation | |
| JP2024507221A5 (enExample) | ||
| JP2024525222A5 (enExample) | ||
| US20210205272A1 (en) | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 | |
| US20240122881A1 (en) | Combination for use in treating cancers | |
| TW202200147A (zh) | Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療 | |
| Kundu et al. | Somatic mutation: Pharmacogenomics in oncology care | |
| CN117858725A (zh) | Erk1/2和egfr抑制剂组合疗法 | |
| CN117940132A (zh) | Erk1/2和kras g12c抑制剂组合疗法 | |
| TW202317121A (zh) | Erk1/2及egfr抑制劑之組合療法 |